title: Cardiovascular risk factors influence response to biological therapies in psoriasis.
authors.affiliation: Dermatology II, Hospital Universitario Central de Asturias, Oviedo, Spain; Dermatology, Complejo Hospitalario de Pontevedra, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Batalla
authors.affiliation: Dermatology II, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Daniel
authors.initials: D
authors.lastname: González-Fernández
authors.affiliation: Dermatology II, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Leire
authors.initials: L
authors.lastname: González-Lara
authors.affiliation: Dermatology, Complejo Hospitalario de Pontevedra, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Abalde
authors.affiliation: Dermatology, Complejo Hospitalario de Pontevedra, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Salgado-Boquete
authors.affiliation: Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Rubén
authors.initials: R
authors.lastname: Queiro-Silva
authors.affiliation: Molecular Genetics, Hospital Universitario Central de Asturias, Oviedo, Spain; Medicine Department, University of Oviedo, Spain.
authors.forename: Eliecer
authors.initials: E
authors.lastname: Coto
authors.affiliation: Dermatology II, Hospital Universitario Central de Asturias, Oviedo, Spain; Medicine Department, University of Oviedo, Spain. Electronic address: pablocotosegura@gmail.com.
authors.forename: Pablo
authors.initials: P
authors.lastname: Coto-Segura
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D001691:Biological Therapy / Q000009:adverse effects* / Q000379:methods; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000453:epidemiology*; D015897:Comorbidity; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept